Denali Therapeutics

News

Biogen, Denali pull Parkinson's drug after failed trial

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.

News

Parkinson's charity partners Biognosys on biomarker project

A new R&D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.

News

FDA clears Denali's 'game-changer' Hunter syndrome drug

Denali's Avlayah is the first drug for neurological complications associated Hunter syndrome to be approved in the US.

News

Denali's ALS programme suffers another setback

Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.

News

Denali slides after ALS drug flunks clinical test

Another clinical trial setback disappoints the ALS patient community, this time involving Denali's eIF2B agonist DNL343.

News

First rare disease therapies chosen for FDA START programme

An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen

Biogen, Denali pull Parkinson's drug after failed trial

Parkinson's charity partners Biognosys on biomarker project

FDA clears Denali's 'game-changer' Hunter syndrome drug

Denali's ALS programme suffers another setback

Denali slides after ALS drug flunks clinical test

First rare disease therapies chosen for FDA START programme

Closing the global evidence gap in oncology, with Flatiron H...

Securing your ROI: Turning post-acquisition integration into...

Denali Therapeutics

Editor's Picks